|
IT1110460B
(it)
*
|
1977-03-02 |
1985-12-23 |
Ciba Geigy Ag |
Prodotti che favoriscono la crescita delle piante e prodotti che proteggono le piante a base di eteri di ossime e di esteri di ossime loro preparazione e loro impiego
|
|
FR2639942B1
(fr)
*
|
1988-12-02 |
1991-03-29 |
Sanofi Sa |
Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
|
|
US5665756A
(en)
*
|
1994-08-03 |
1997-09-09 |
Hoechst Marion Roussel, Inc. |
Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders
|
|
US6548084B2
(en)
*
|
1995-07-20 |
2003-04-15 |
Smithkline Beecham Plc |
Controlled release compositions
|
|
DK0759299T3
(da)
*
|
1995-08-16 |
2000-08-07 |
Lilly Co Eli |
Potensering af serotoninrespons
|
|
IN182588B
(enExample)
|
1998-05-12 |
1999-05-08 |
Sun Pharmaceutical Ind Ltd |
|
|
IE990406A1
(en)
|
1999-05-20 |
2000-12-27 |
Elan Corp Plc |
Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
|
|
IN186677B
(enExample)
|
1999-11-12 |
2001-10-20 |
Sun Pharmaceutical Ind Ltd |
|
|
EP1284729A4
(en)
*
|
2000-04-13 |
2007-12-19 |
Mayo Foundation |
A- (BETA) -42 DECREASING MEDICINAL PRODUCTS
|
|
US20080021085A1
(en)
*
|
2000-04-13 |
2008-01-24 |
Mayo Foundation For Medical Education And Research |
Method of reducing abeta42 and treating diseases
|
|
WO2001080845A2
(en)
|
2000-04-24 |
2001-11-01 |
Aryx Therapeutics |
(2-aminoethyl) oxime derivatives for the treatment of depression
|
|
US7256191B2
(en)
*
|
2000-04-24 |
2007-08-14 |
Aryx Therapeutics |
Materials and methods for the treatment of depression
|
|
US7119083B2
(en)
*
|
2001-10-12 |
2006-10-10 |
Azevan Pharmaceuticals, Inc. |
β-Lactamyl vasopressin V1a Antagonists
|
|
AU2003217676B2
(en)
|
2002-02-22 |
2009-06-11 |
Takeda Pharmaceutical Company Limited |
Active agent delivery systems and methods for protecting and administering active agents
|
|
WO2004071431A2
(en)
*
|
2003-02-05 |
2004-08-26 |
Myriad Genetics, Inc. |
Method and composition for treating neurodegenerative disorders
|
|
AU2004311577A1
(en)
*
|
2003-07-11 |
2005-07-21 |
Myriad Genetics, Inc. |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
|
|
MXPA06002789A
(es)
|
2003-09-12 |
2006-06-14 |
Pfizer |
Combinaciones que comprenden ligandos alfa-2-delta.
|
|
ATE473967T1
(de)
*
|
2003-11-26 |
2010-07-15 |
Pfizer Prod Inc |
Aminopyrazolderivate als gsk-3-inhibitoren
|
|
PL1691811T3
(pl)
|
2003-12-11 |
2014-12-31 |
Sunovion Pharmaceuticals Inc |
Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
|
|
US20070293538A1
(en)
*
|
2004-04-13 |
2007-12-20 |
Myriad Genetics, Incorporated |
Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
|
|
US20050233010A1
(en)
*
|
2004-04-19 |
2005-10-20 |
Satow Philip M |
Lithium combinations, and uses related thereto
|
|
MXPA06012165A
(es)
*
|
2004-04-29 |
2007-01-17 |
Keystone Retaining Wall System |
Chapas para muros, muros de contencion y similares.
|
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
CA2618985A1
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
CA2601709C
(en)
|
2005-03-22 |
2017-02-14 |
Azevan Pharmaceuticals, Inc. |
Beta-lactamylalkanoic acids
|
|
GT200600158A
(es)
*
|
2005-04-22 |
2006-11-28 |
|
Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina
|
|
AU2006239942A1
(en)
*
|
2005-04-22 |
2006-11-02 |
Wyeth |
Dihydrobenzofuran derivatives and uses thereof
|
|
GT200600164A
(es)
|
2005-04-22 |
2007-03-14 |
|
Derivados de dihidrobenzofuranos y usos de los mismos
|
|
CA2605554A1
(en)
*
|
2005-04-22 |
2006-11-02 |
Wyeth |
Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
|
|
WO2007008758A2
(en)
*
|
2005-07-08 |
2007-01-18 |
Braincells, Inc. |
Methods for identifying agents and conditions that modulate neurogenesis
|
|
US20070015832A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Myriad Genetics, Incorporated |
Methods of treating overactive bladder and urinary incontinence
|
|
BRPI0613664B1
(pt)
|
2005-07-19 |
2021-08-24 |
Azevan Pharmaceuticals, Inc |
Compostos antagonistas de beta-lactamil fenilalanina, cisteína e serina vasopressina, composição farmacêutica que compreende ditos compostos e usos terapêuticos dos mesmos
|
|
KR20080039876A
(ko)
*
|
2005-07-22 |
2008-05-07 |
미리어드 제네틱스, 인크. |
높은 약물 충진 제형 및 투여형
|
|
EP2377530A3
(en)
|
2005-10-21 |
2012-06-20 |
Braincells, Inc. |
Modulation of neurogenesis by PDE inhibition
|
|
JP2009513672A
(ja)
|
2005-10-31 |
2009-04-02 |
ブレインセルス,インコーポレイティド |
神経発生のgaba受容体媒介調節
|
|
FR2912057B1
(fr)
*
|
2007-02-07 |
2009-04-17 |
Sanofi Aventis Sa |
Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
CN101410112A
(zh)
*
|
2006-03-24 |
2009-04-15 |
惠氏公司 |
治疗抑郁症的新治疗组合
|
|
JP4615470B2
(ja)
*
|
2006-03-29 |
2011-01-19 |
卓郎 簑和田 |
大脳の認知力を用いた疾患治療・予防の方法および医薬
|
|
MX2008014320A
(es)
|
2006-05-09 |
2009-03-25 |
Braincells Inc |
Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
|
|
EP2021000A2
(en)
|
2006-05-09 |
2009-02-11 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
US7858611B2
(en)
*
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
|
US20080033045A1
(en)
*
|
2006-07-07 |
2008-02-07 |
Myriad Genetics, Incorporated |
Treatment of psychiatric disorders
|
|
TW200817003A
(en)
*
|
2006-07-31 |
2008-04-16 |
Sanofi Aventis |
Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
|
|
JP2010502722A
(ja)
|
2006-09-08 |
2010-01-28 |
ブレインセルス,インコーポレイティド |
4−アシルアミノピリジン誘導体を含む組み合わせ
|
|
WO2008034032A2
(en)
*
|
2006-09-14 |
2008-03-20 |
Azevan Pharmaceuticals, Inc. |
Beta-lactam cannabinoid receptor modulators
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
WO2008083204A2
(en)
*
|
2006-12-28 |
2008-07-10 |
Braincells, Inc. |
Modulation of neurogenesis by melatoninergic ligands
|
|
CA2675132A1
(en)
*
|
2007-01-11 |
2008-07-17 |
Braincells, Inc. |
Modulation of neurogenesis with use of modafinil
|
|
EP2288345B1
(en)
|
2008-04-18 |
2015-06-10 |
University College Dublin National University Of Ireland, Dublin |
Psycho-pharmaceuticals
|
|
US20100092479A1
(en)
*
|
2008-08-18 |
2010-04-15 |
Combinatorx (Singapore) Pte. Ltd. |
Compositions and methods for treatment of viral diseases
|
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
WO2011050198A1
(en)
|
2009-10-23 |
2011-04-28 |
Janssen Pharmaceutica Nv |
Disubstituted octahy - dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
|
|
AU2010328186B2
(en)
|
2009-12-08 |
2014-12-18 |
Case Western Reserve University |
Compounds and methods of treating ocular disorders
|
|
PL3351104T3
(pl)
|
2010-07-01 |
2021-06-14 |
Azevan Pharmaceuticals, Inc. |
Związki do stosowania w leczeniu okresowych zaburzeń wybuchowych
|
|
US20140010883A1
(en)
|
2011-03-17 |
2014-01-09 |
Lupin Limited |
Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
|
|
KR101427221B1
(ko)
*
|
2012-08-29 |
2014-08-13 |
주식회사 에스텍파마 |
플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
|
|
PT2981518T
(pt)
*
|
2013-04-03 |
2021-06-04 |
Zcl Chemicals Ltd |
Um processo melhorado para a preparação de maleato de fluvoxamina
|
|
EP3104847B8
(en)
|
2014-02-07 |
2020-12-30 |
Támogatott Kutatócsoportok Irodája |
Novel use of sigma-1 receptor agonist compounds
|
|
SG11201608064WA
(en)
|
2014-03-28 |
2016-10-28 |
Azevan Pharmaceuticals Inc |
Compositions and methods for treating neurodegenerative diseases
|
|
PH12018501903B1
(en)
|
2016-03-10 |
2023-03-17 |
Janssen Pharmaceutica Nv |
Methods of treating depression using orexin-2 receptor antagonists
|
|
ES2926179T3
(es)
|
2016-11-24 |
2022-10-24 |
Sigmadrugs Kutato Korlatolt Feleloessegue Tarsasag |
Utilización de composiciones para la conservación de órganos/tejidos
|
|
CA3075759A1
(en)
|
2017-09-15 |
2019-03-21 |
Azevan Pharmaceuticals, Inc. |
Compositions and methods for treating brain injury
|
|
WO2021016112A2
(en)
|
2019-07-19 |
2021-01-28 |
Bioxcel Therapeutics, Inc. |
Non-sedating dexmedetomidine treatment regimens
|
|
US11806334B1
(en)
|
2023-01-12 |
2023-11-07 |
Bioxcel Therapeutics, Inc. |
Non-sedating dexmedetomidine treatment regimens
|